Quote this publication Share Print

AVASTIN (bevacizumab), monoclonal antibody - OVARIAN CANCER

Opinions on drugs - Posted on Oct 13 2016

Reason for request

Re-assessment of the actual benefit and the improvement in actual benefit

Minor improvement in the treatment of advanced stage ovarian cancer

  • AVASTIN has Marketing Authorisation in combination with carboplatin and paclitaxel in the first-line treatment of advanced stage epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
  • The addition of bevacizumab to carboplatin and to paclitaxel has demonstrated a modest effect on progression-free survival, without impacting the overall survival, but with an addition of adverse events such as bleeding, arterial hypertension and gastrointestinal perforations compared to carboplatin and paclitaxel.

Clinical Benefit



Clinical Added Value



Contact Us

Évaluation des médicaments